1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Arecor Therapeutics PLC

Arecor Therapeutics PLC

LLSE:AREC
82.80
GBX
+0.30
(+0.36%)
3.04BMarket Cap
Apr 27Next Earn
Arecor Therapeutics PLC
LSE:AREC
(London Stock Exchange)

Recent

price

82.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
GBP
- -
0.05
0.03
0.06
0.05
0.08
0.15
0.05
0.05
- -
Revenue per Share
- -
-0.04
-0.09
-0.1
-0.27
-0.32
-0.28
-0.31
0.02
- -
Basic EPS, GAAP
- -
-0.02
-0.09
-0.07
-0.24
-0.38
-0.2
-0.28
-0.07
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.05
0.02
0.15
0.03
0.67
0.57
0.31
0.14
0.17
0.17
Book Value per Share
0.05
0.02
0.15
0.03
0.67
0.46
0.2
0.14
0.17
0.17
Tangible Book Value per Share
28
28
28
28
23
29
31
33
38
38
Basic Weighted Avg Shares
- -
1
1
2
1
2
5
2
2
- -
Sales/Revenue/Turnover
- -
-103.53
-381.85
-201.88
-556.04
-437.45
-200.63
-315.03
-236
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-2
-3
-6
-9
-9
-10
1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
6.24
- -
Effective Tax Rate (%)
- -
-82.9
-325.72
-162.07
-532.73
-385.35
-187.05
-623.01
38.74
- -
Profit Margin (%)
1
1
4
2
18
14
6
5
6
6
Working Capital
- -
1
- -
2
- -
- -
- -
- -
- -
- -
LT Debt
1
1
4
1
19
17
10
5
6
6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
14.2
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
11.12
- -
Return on Capital (%)
- -
-111.82
-99.68
-110.3
-63.85
-51.44
-63.41
-137.62
11.25
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
38
Market Capitalization
28
16
30

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
8
5
8
Cash, Cash Equivalents & STI
3
2
6
Accounts Receivable, Net
3
2
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
2
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
444.4%
20.66%
Free Cash Flow
- -
45.35%
-73.63%
Net Income, GAAP
- -
15.96%
-106.49%
Sales/Revenue/Turnover
- -
21.25%
4.32%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
5
2024
- -
- -
2
2025
- -
- -
2

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.28
2024
- -
- -
-0.31
2025
- -
- -
0.02

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Arecor Therapeutics plc Arecor Therapeutics plc, a clinical-stage biopharmaceutical company listed on the London Stock Exchange, develops enhanced formulations of existing therapeutic medicines using its proprietary Arestat platform to improve stability, performance, and patient outcomes in areas including diabetes, obesity, and hospital care. The company offers an internal proprietary portfolio comprising AT278, a concentrated rapid-acting insulin for Type 2 diabetes; AT247, an ultra-rapid acting insulin for artificial pancreas systems; and Oral GLP-1, an oral formulation for diabetes and obesity treatments; alongside partnered programs such as ready-to-administer hospital products licensed to Hikma Pharmaceuticals, biosimilars like AT220, and other peptide therapies reformulated for superior properties including extended shelf-life, room-temperature stability, and high-concentration delivery. Founded in 2007 and headquartered at Chesterford Research Park in Little Chesterford, United Kingdom, Arecor Therapeutics plc operates globally, partnering with pharmaceutical, biotechnology, and medtech firms to co-develop differentiated biosimilars, vaccines, monoclonal antibodies, and ready-to-use formats targeting patients with unmet needs in endocrinology and acute care settings. Recent developments include a September 2025 co-development agreement with Sequel Med Tech for integration of AT278 with its automated insulin delivery system; a royalty financing deal with Ligand Pharmaceuticals yielding up to $11 million in non-dilutive funding from AT220 and AT292 royalties to extend cash runway into mid-2027; enhanced intellectual property filings in November 2025 for AT278 and oral delivery technology; executive and non-executive board changes in September 2025; and a decision in January 2025 to cease operations of subsidiary Tetris Pharma.